State Street SPDR S&P Biotech ETF
397 hedge funds and large institutions have $3.88B invested in State Street SPDR S&P Biotech ETF in 2017 Q4 according to their latest regulatory filings, with 93 funds opening new positions, 124 increasing their positions, 112 reducing their positions, and 43 closing their positions.
116% more first-time investments, than exits
New positions opened: 93 | Existing positions closed: 43
14% more funds holding
Funds holding: 349 → 397 (+48)
11% more repeat investments, than reductions
Existing positions increased: 124 | Existing positions reduced: 112
6.06% more ownership
Funds ownership: 90.14% → 96.2% (+6.1%)
3% more capital invested
Capital invested by funds: $3.77B → $3.88B (+$113M)
6% less funds holding in top 10
Funds holding in top 10: 18 → 17 (-1)
71% less call options, than puts
Call options by funds: $537M | Put options by funds: $1.85B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$120M |
| 2 |
Citigroup
New York
|
+$117M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$74.5M |
| 4 |
Barclays
London,
United Kingdom
|
+$49.9M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$41.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$101M |
| 2 |
JP Morgan Chase
New York
|
-$95.4M |
| 3 |
QIM
Quantitative Investment Management
Charlottesville,
Virginia
|
-$59.3M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$40.7M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$38.6M |
XBI Hedge Fund Activity: Q4 2017 in Review
397 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q4 2017, worth a combined $3.88B — up 3% from $3.77B a quarter earlier.
Buyers outnumbered sellers: 93 funds opened new XBI positions and 43 closed out — a net gain of 50 holders — while 124 added to existing stakes and 112 trimmed.
The largest buyer was UBS Group, adding an estimated $120M. The largest seller was Credit Suisse, cutting an estimated $101M.
- 397 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q4 2017, up from 349 in Q3 2017.
- Funds reported $3.88B of State Street SPDR S&P Biotech ETF stock for Q4 2017, up 3% quarter-over-quarter.
- 93 funds opened new State Street SPDR S&P Biotech ETF positions in Q4 2017 and 43 closed out, a net change of +50 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q4 2017 was UBS Group, an estimated $120M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q4 2017 was Credit Suisse, an estimated $101M sold.
Based on aggregated 13F filings for Q4 2017.